Clinical Trial Detail

NCT ID NCT01967823
Title T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

meningioma

Advanced Solid Tumor

melanoma

Therapies

Aldesleukin + Anti-NY ESO-1 mTCR PBL + Cyclophosphamide + Fludarabine

Age Groups: adult senior child

No variant requirements are available.